Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

US Patent 11964016 · Granted Apr 23, 2024

Estimated economic value: $91,561,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments2025
Anti-MSR1 antibodies and methods of use thereof2025
Mice that make VL binding proteins2025
Mouse model of DITRA disease and uses thereof2025
Methods for modifying a genome2025
Compositions and methods for using bispecific antibodies to bind complement and 2025
Anti-TMPRSS6 antibodies and uses thereof2025
Human antibodies to artemin and methods of use thereof2025
Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bi2025
Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bi2025
Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bi2025
Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof2025